SH-748 is under clinical development by Nanjing Sanhome Pharmaceutical and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma). According to GlobalData, Phase II drugs for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SH-748’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SH-748 overview
SH-748 is under development for the treatment of relapsed or refractory Peripheral T Cell Lymphomas including peripheral T-cell lymphoma unspecified(PTCL-U), angioimmunoblastic T-cell lymphoma(AITL), ALK+/ALK-anaplastic large cell lymphoma(ALCL), subcutaneous panniculitis-like T-cell lymphoma(SPTL), hematological tumors such as relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma and extranodal marginal zone B-cell lymphoma and splenic marginal zone B-cell lymphoma. The drug candidate is administered through oral route as a tablet. It acts by targeting phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit delta (PIK3delta).
For a complete picture of SH-748’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
